Country Business Reports interviews and articles by Discovery Reports

The first step most needed to treat a disease is to get a quick and accurate diagnosis. Existing clinical laboratories that provide blood tests require dedicated resources such as infrastructure, technicians, water supply and electricity, which take a lot of time and money for patients and hospitals. What if a fully automated, artificially intelligent device could provide morphology-based diagnostics, replacing clinical laboratories?

With Noul’s miLab, an artificial intelligence (AI) driven on-site diagnostics platform, this concept becomes a reality. Noul, the South Korean technology-based bio-diagnostics start-up, has developed the innovative miLab platform to enable laboratory-grade diagnostic results with one small device. The miLab platform can provide an accurate blood diagnosis by automatically analysing a drop of blood extracted from a finger within 15 minutes.

The miLab platform has four key features – the miLab itself, a cartridge with all reagents fully integrated, embedded AI technology, and a data surveillance and monitoring system linked to the software viewer.

Among these features, the most important patented core technology is the Next Generation Staining and Immunoassay (NGSI), a solid-based staining method using automated sample preparation. NGSI can replace the current liquid-based sample preparation methods and possesses the potential to expand applicability to other diagnostic areas.